01 September 2005
Gelstat Migraine((R)) (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase.
Roger K. Cady, Curtis P. Schreiber, Mary E. Beach, Carolyn C. HartMed Sci Monit 2005; 11(9): PI65-69 :: ID: 428456
Abstract
Background: Treatment of migraine headaches is often delayed due to assessingthe potential severity of an evolving headache or anticipating unwanted consequences from prescriptionmedication. Studies have demonstrated improved pain-free response when prescription treatments are takenduring the mild headache phase of a migraine. This study was designed to evaluate the efficacy of anOTC product, GelStat Migraine((R)), when taken in the early, mild pain phase of migraine. Material/Methods:An open-label study enrolling 30 subjects, male and female, with a one-year history of migraine meetingIHS diagnostic criteria with or without aura, 2-8 migraines per month and 15 headache days per month.Inclusion required having migraines that consistently started at mild and worsened to moderate or severe,if untreated, in at least 75% of attacks. Subjects also had to be able to distinguish migraine from non-migraineheadaches and reliably identify migraine early in the course of an attack. One headache was treated inthe mild pain phase with GelStat Migraine((R)), a combination of feverfew and ginger. Results: 29 evaluablesubjects completed the study, all treating at mild pain. Two hours after treatment, 48% were pain-freewith 34% reporting a headache of only mild severity. 29% reported a recurrence within 24 hours. Sideeffects were minimal and not serious. 59% of subjects were satisfied with Gelstat Migraine((R)) therapyand 41% preferred GelStat Migraine((R)) or felt it was equal to their pre-study medication. Conclusions:GelStat Migraine((R)) is effective as a first line abortive treatment for migraine when initiated earlyduring the mild headache phase.
Keywords: Administration, Sublingual, Analgesics - therapeutic use, Ginger, Migraine Disorders - physiopathology, Nonprescription Drugs, Pain - physiopathology, Phytotherapy, Tanacetum parthenium
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
06 Mar 2024 : Clinical Research
Comparison of Outcomes between Single-Level and Double-Level Corpectomy in Thoracolumbar Reconstruction: A ...Med Sci Monit In Press; DOI: 10.12659/MSM.943797
21 Mar 2024 : Meta-Analysis
Economic Evaluation of COVID-19 Screening Tests and Surveillance Strategies in Low-Income, Middle-Income, a...Med Sci Monit In Press; DOI: 10.12659/MSM.943863
10 Apr 2024 : Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Dep...Med Sci Monit In Press; DOI: 10.12659/MSM.942612
06 Mar 2024 : Clinical Research
Enhanced Surgical Outcomes of Popliteal Cyst Excision: A Retrospective Study Comparing Arthroscopic Debride...Med Sci Monit In Press; DOI: 10.12659/MSM.941102
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952